Non-Cationic Proteins Are Associated with HIV Neutralizing Activity in Genital Secretions of Female Sex Workers

Kenzie D. M. Birse1,2*, Amy L. Cole3, Taha Hirbod4, Lyle McKinnon5, Terry B. Ball1,2,7, Garrett R. Westmacott6, Joshua Kimani7, Frank Plummer1,2,6,7, Alexander M. Cole3, Adam Burgener1,2,4, Kristina Broliden4

1 Proteomics Unit, National Laboratory for HIV Immunology, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, 2 Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada, 3 Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida, United States of America, 4 Unit of Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5 Centre for the AIDS Programme of Research In South Africa, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Congella, South Africa, 6 National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, 7 Department of Medical Microbiology, Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya

* ummogkk@myumanitoba.ca

Abstract

Objective

Cationic proteins found in cervicovaginal secretions (CVS) are known to contribute to the early antiviral immune response against HIV-infection in vitro. We here aimed to define additional antiviral factors that are over-expressed in CVS from female sex workers at high risk of infection.

Methods

CVS were collected from Kenyan HIV-seronegative (n = 34) and HIV-seropositive (n = 12) female sex workers, and were compared with those from HIV-seronegative low-risk women (n = 12). The highly exposed seronegative (HESN) sex workers were further divided into those with less (n = 22) or more (n = 12) than three years of documented sex work. Cationic protein-depleted CVS were assessed for HIV-neutralizing activity by a PBMC-based HIV-neutralizing assay, and then characterized by proteomics.

Results

HIV neutralizing activity was detected in all unprocessed CVS, however only CVS from the female sex worker groups maintained its HIV neutralizing activity after cationic protein-depletion. Differentially abundant proteins were identified in the cationic protein-depleted secretions including 26, 42, and 11 in the HESN>3yr, HESN<3yr, and HIV-positive groups, respectively. Gene ontology placed these proteins into functional categories including proteolysis, oxidation-reduction, and epidermal development. The proteins identified in this
study include proteins previously associated with the HESN phenotype in other cohorts as well as novel proteins not yet associated with anti-HIV activities.

Conclusion
While cationic proteins appear to contribute to the majority of the intrinsic HIV neutralizing activity in the CVS of low-risk women, a broader range of non-cationic proteins were associated with HIV neutralizing activity in HESN and HIV-positive female sex workers. These results indicate that novel protein factors found in CVS of women with high-risk sexual practices may have inherent antiviral activity, or are involved in other aspects of anti-HIV host defense, and warrant further exploration into their mode of action.

Introduction
HIV-seronegative women who have had frequent sexual HIV exposures over many years have been shown to mount an efficient innate and HIV-specific immune response in the genital tract mucosa despite their uninfected status [1]. HIV-neutralizing IgA and innate immune factors including cationic proteins, CCR5-ligands and antiproteases have been found in genital tract secretions of various HIV-exposed seronegative (HESN) cohorts such as female sex workers and HIV serodiscordant couples [2–6]. Many cationic proteins have a synergistic antimicrobial effect and HIV neutralizing capacity in vitro [7], and constitute an important arm of innate immunity against pathogens at genital mucosal surfaces. Expression of innate immune proteins is normally regulated by various factors including sex hormones, inflammatory conditions and the local microflora [8–12]. Furthermore, their functional capacity can vary depending on their local distribution, concentration and interaction with other molecules at the mucosal site [13]. The mechanisms of immune protection from heterosexual transmission of HIV infection are thus complex and have not been extensively studied in vivo. Mucosal samples collected from HESN populations are a useful tool to complement in vitro experiments and non-human primate studies to explore such local immune activities.

As genital secretions are known to contain many hundreds, if not thousands, of unique proteins [14,15], many with antimicrobial and antiviral functions, it is likely that multiple factors contribute to the host defense against HIV. This has however not been fully explored since most studies have only examined predefined factors. Understanding the complexity of factors contributing to HIV neutralizing activity can be performed comprehensively using systems biology approaches. In the present study we examined cervicovaginal secretions (CVS) from HIV-seronegative and HIV-seropositive female sex workers as well as CVS from HIV-seronegative low-risk women not participating in sex work. CVS samples were tested for HIV neutralization and were analyzed via mass spectrometry to identify proteins that could potentially be contributing to this effect. Here, this study identified novel protein factors within the cationic protein-depleted fraction of the mucosa that may be involved in the intrinsic antiviral nature of cervicovaginal compartment and host defense against heterosexual HIV transmission in addition to the well-described effects of various cationic proteins [7,16].

Material and Methods
Study population
HESN and HIV-seropositive female sex workers were recruited through the Pumwani Sex Worker Cohort [17] and HIV-seronegative low-risk women were recruited through a Maternal...
Health Clinic based at the Pumwani Maternity Hospital [18]. All sex worker participants enrolled were currently active in sex work whereas all low-risk women enrolled reported no history of sex work. Although their partner was not tested for HIV serology these women were considered to be significantly less exposed to HIV than the study participants in the sex worker groups. All women underwent a full physical examination and sexually transmitted infections (STI) testing at enrolment; diagnostics included HIV serology, urine for Chlamydia trachomatis and Neisseria gonorrhoeae molecular testing; syphilis serology; and Gram stain for Nugent scoring. All participants were provided with HIV/STI prevention counseling, male and female condoms, family planning services, treatment of STIs, medical care for acute and chronic illnesses, access to adequate diagnostic testing and referral for specialist consultant and/or hospitalization as needed. This study was reviewed and approved by the research ethics boards at Kenyatta National Hospital (Nairobi, Kenya); The Regional Ethical Review Board in Stockholm, Sweden; and the Research Ethics Board of the University of Manitoba (Winnipeg, Canada). All study participants provided written informed consent.

Cervicovaginal Fluid Collection
CVS were collected by rotating a cotton swab 360° in the outer part of the endocervix and by rotating a different swab across the vaginal wall. Both swabs were placed in the same tube containing 0.5 ml sterile phosphate buffered saline, which was immediately placed on ice. The samples were then transported from the clinic to the laboratory on ice and centrifuged at 800 g for 10 minutes at 4°C. Supernatants were separated from the cell pellet and stored at -80°C.

HIV neutralization assay
HIV neutralization assays were performed according to a predefined protocol and neutralization cut off [19,20]. Prior to this assay, the IgG fraction of the CVS samples from the HIV seropositive women was removed to avoid IgG-mediated HIV-specific neutralizing activity [21]. The IgG-depleted fraction was stored at -80°C until use. The other study groups were by definition HIV IgG seronegative and their CVS samples were therefore left intact. For the HIV neutralizing assay, an R5 tropic primary isolate of HIV subtype A (isolate 92UG037; AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH) was used. The CVS sample volume did not allow assessment with additional virus isolates. To account for variations in TCID50 depending on PBMC donor variability, three viral dilutions were used in each assay and a TCID50 of 10–50 was finally selected for evaluation. Duplicate wells of 75 μl of each virus dilution and 75 μl of each sample fraction (undiluted) were incubated for 1 hour at 37°C followed by addition of a mixture of 1 x 10^5 PHA-P-stimulated PBMC from two donors. After 24 hour incubation at 37°C, the cells were centrifuged; unbound virus was washed away, and 200 μl of fresh medium were added to each well. On day 3, 120 μl of medium was discarded and replaced with new medium, after which day 6 supernatants were collected for analysis of virus production with a p24 antigen ELISA (Vironostika HIV-1 Antigen; Electra-Box Diagnostica AB, Stockholm, Sweden). Neutralization was defined as a ≥67% reduction of p24 antigen in the supernatant as compared with p24 antigen content when the virus isolate was incubated in the presence of a standard pool of Swedish HIV seronegative heat-inactivated plasma samples diluted 1:20.

Selective depletion of cationic proteins from CVS
Carboxymethyl (CM) weak cation exchange resin (Bio-Rad) was used to deplete cationic proteins from vaginal fluid [7]. The CM resin was pre-equilibrated by washing 6 times with a buffer resembling vaginal fluid in electrolyte composition (60mM NaCl, 20mM potassium phosphate, pH 6) [22]. Equal volumes of CVS from four to six HIV seronegative donors were
centrifuged and pooled before the extraction of cationic proteins. From each pool, 0.5 mL CVS was reserved and stored at -80°C as “unprocessed CVS”. The remaining volume from each pool was CM-extracted by mixing with equilibrated CM resin at 4°C overnight in an end-over-end tumbler. Centrifugation (15,000xg, 4°C, 3min) enabled collection of the CM-depleted CVS supernatant, which was then cleared of residual resin by additional centrifugations and stored at -80°C. The CM resin sediment was washed 5 times with 25mM ammonium acetate, pH 7, and then cationic proteins were extracted by incubating the washed resin with 5% acetic acid in a tumbler at 4°C. Extracted proteins were collected and stored at -80°C after 2 h, and the resin was extracted a second time by incubation with more acetic acid overnight in a tumbler at 4°C. The first and second cationic extracts were pooled, clarified of residual resin, concentrated by vacuum centrifugation, and restored to the original volume. All samples were stored at -80°C until use.

**Protein Digestion and Preparation for MS Analysis**

The protein content of the cationic protein-depleted CVS samples was measured by standard BCA protein assay (Novagen). Ten micrograms from each sample was added to ammonium bicarbonate buffer (100mM, Sigma) to a total volume of 100μl. Five microliters of dithiothreitol (DTT, 200mM, Sigma) was added to each sample. Samples were vortexed, centrifuged and incubated at 60°C while gently shaking for 1 hour. Twenty microliters of iodoacetamide (200mM, Sigma) was then added to each sample. Samples were vortexed, centrifuged and incubated at room temperature for 30 minutes in the dark. Eleven microliters of DTT (200mM) was added after this 30 minute incubation to neutralize any further iodoacetamide activity (to prevent alkylation of trypsin). Samples were again vortexed, spun down and incubated at room temperature in the dark for 1 hour. Trypsin (Promega) was added (2ug/sample) and incubated at 37°C overnight. Peptides were dried via vacuum centrifugation the following morning and stored at -80°C. The samples were then cleaned of salts and detergents by reversed-phase liquid chromatography (high pH RP, Agilent 1200 series micro-flow pump, Water XBridge column) using a step-function gradient such that all peptides elute into a single fraction for each sample. The fractions were then dried via vacuum centrifugation and kept at -80°C until analyzed by mass spectrometry.

**Mass Spectrometry Analysis**

Fractions were re-suspended in 2% acetonitrile (Fisher Scientific), 0.1% formic acid (EMD Canada) and injected into a nano-flow Easy nLC II connected in-line to an LTQ Orbitrap Velos mass spectrometer with a nanoelectrospray ion source at 2.35 kV (Thermo Fisher Scientific, San Jose, CA, USA). The peptide fractions were loaded onto a C18-reversed phase trap column (2 cm long, 100 μm inner diameter, 5 μm particles) with 100% buffer A (2% acetonitrile, 0.1% formic acid) at 3 μl/min for a total volume of 30 μl, and then separated on a C18-reversed phase column (15 cm long, 75 μm inner diameter, 3 μm particles). Both columns were packed in-house with ReproSil-Pur C18-AQ resin (Dr. Maisch) and fritted with Kasil. Peptides were eluted using a linear gradient of 2–32% buffer B (98% acetonitrile, 0.1% formic acid) over 120 min at a constant flow rate of 250 nl/min. Total LC/MS/MS run-time was 160 minutes, including the loading, linear gradient, column wash at 95% buffer B, and the equilibration.

Data were acquired using a data-dependent method, dynamically choosing the top 10 abundant precursor ions from each survey scan for isolation in the LTQ (2.0 m/z isolation width) and fragmentation by CID (35% normalized collision energy, with 10 ms activation time). The survey scans were acquired in the Orbitrap over m/z 300–1700 with a target resolution of 60000 at m/z 400, and the subsequent fragment ion scans were acquired in the LTQ Velos over
a dynamic m/z range. The lower threshold for selecting a precursor ion for fragmentation was 1000 ions. Dynamic exclusion was enabled using a list size of 500 features, a m/z tolerance of 15 ppm, a repeat count of 1, a repeat duration of 30 s, and an exclusion duration of 15 s, with early expiration disabled. Lock Mass was used with polysiloxane. All spectra were processed using Mascot Distiller v2.4.3.1 (Matrix Science) and database searching was done with Mascot v2.4.0 (Matrix Science). Searches were against the SwissProt database (2013–04). The minimum number of unique peptides required for protein identification was set to one peptide and false discovery rates (Prophet) were required to be below 1% for both peptide and protein identification. Relative protein levels were calculated using label-free analysis based on precursor ion peak intensities calculated using Progenesis LC-MS v.4.0 (Nonlinear Dynamics). Complete details regarding the proteomic data set including normalized abundance, number of unique peptides identified and percent coverage are available in S1 Table and are available online (http://figshare.com/articles/Non_cationic_proteins_are_associated_with_HIV_neutralizing_activity_in_genital_secretions_of_female_sex_workers/1428626).

Statistical & Bio-functional Analysis

Protein abundances were normalized by mean division and log2 transformation. Statistical analysis was performed by Student’s T-tests (Perseus, v1.3.0.4, Max Planck Institute of Biochemistry). The significance threshold was set as $\alpha = 0.05$ and fold changes greater than or equal to 2 (Log2 Fold Change = 1). Statistically significant results were entered into Ingenuity Pathway Analysis (Qiagen), Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 [23,24] and examined using the UniProt website to determine bio-functional associations. A minimum of two associated proteins and Benjamini-Hochberg corrected Fisher’s Exact Tests were used to determine significant bio-functional associations.

Results

Demographic data of the study groups

Analysis of CVS was performed by pooling samples from five to seven women into the following study groups: HIV-seronegative low-risk women (low-risk, n = 12 into 2 pools), HESN female sex workers (n = 34 into 6 pools, divided according to more (2 pools) or less (4 pools) than 3 years of sex work), and HIV-seropositive female sex workers (HIV positive, n = 12 into 2 pools). Sample pooling was required due to the limited quantity of CVS collected and the amounts required for the subsequent assays included in this study. The pools were designed to contain comparable numbers of samples from women in the early and late menstrual cycle stage, and comparable numbers of women using hormonal contraception (oral contraceptives, n = 8, injectable contraceptives, n = 7 or no hormonal contraception use, n = 43) to limit potential confounding effects of the influence of sex hormones on the protein composition (data not shown). None of the samples represented cases of ongoing infections with *Chlamydia trachomatis*, Neisseria gonorrhoeae or syphilis. Women with clinical signs of genital ulcers or inflammation were excluded from the study. Bacterial vaginosis (here defined as gram stain for Nugent scoring $\geq 7$) was diagnosed in 0 of 12 low-risk women, in 5 of 24 women in the HESN<$\textless$3yr sex worker group, in 1 of 12 women in the HESN$\geq$3yr sex worker group, and in 1 of 12 women in the HIV-seropositive sex worker group.
Cationic protein-depleted CVS samples of the FSW study groups can neutralize HIV

In the first set of experiments, the intrinsic HIV-neutralizing capacity was assessed in the unprocessed sample pools. In a previous study the pools representing the low-risk study group were shown to neutralize HIV as defined by a PBMC-based assay using a primary HIV isolate of the R5 phenotype/subtype A [25]. Likewise, all pools representing the sex worker (HESN \( \geq \) 3yr, HESN \(<\) 3yr and HIV positive) study groups were here shown to neutralize HIV infection using the same experimental conditions (Fig 1). Next, the cationic proteins were selectively removed from the CVS pools while sparing the concentrations of the remaining proteins and other non-positively charged molecules. The removal of cationic proteins was confirmed by AU-PAGE for all pools (data not shown), thus suggesting that biologically relevant concentrations were depleted. Traces of such peptide fragments could be detected by mass-spectrometry; however the fragments detected may represent inactive remnants of the original proteins (data not shown).

In our previous study we reported a lack of HIV-neutralizing activity in cationic protein-depleted CVS of low-risk women [25]. Thus, the majority of the functional activity was mediated by the cationic protein fraction for these low-risk uninfected women. To test whether this effect was the same in high-risk groups, the sex worker study groups were assessed using the same experimental conditions and showed significant HIV neutralizing activity despite the
depletion of the cationic protein fractions (Fig 1). The sample pools representing the HIV positive women had been depleted of IgG prior to the cationic protein-depletion to exclude functional activity mediated by HIV-specific IgG antibodies.

Proteomic analysis of cationic protein-depleted CVS from all study groups

To define the proteins that were differentially expressed between the study groups, a comprehensive analysis of the depleted fractions was performed by tandem-mass spectrometry proteomic analysis. Relative protein levels were compared using a Student’s t-test ($\alpha = 0.05$, Fold Change$\geq 2$). Three comparisons were made: HESN$>3yr$ versus low-risk women (Table 1); HESN$<3yr$ versus low-risk women (Table 2); and HIV positive sex workers versus low-risk women (Table 3), which identified 26, 42, and 11 host differentially abundant proteins, respectively.

The biological functions associated with the proteins identified as differentially abundant were determined, and there were proteins associated with viral infection and HIV infection in all sex worker groups. Both HESN groups ($>3$ years and $<3$ years) were found to differentially express proteins known to have an effect on viral infection (CYCS, DNAJB1, MT2A, RPS27A, CLTB, CTSB, HMGN2, ALB, ZYX) [27–34] with particular proteins known to increase HIV infection according to the results of in vitro mRNA silencing experiments (CYCS, DNAJB1, MT2A, ZYX, PSME1, BANF1, RPS27A) [35,36]. Despite the depletion of cationic proteins and the remaining expression of HIV infection enhancing proteins, the CVS of both HESN and HIV-positive groups still maintained a relatively strong capacity to neutralize HIV. Other proteins differentially expressed in these groups compared to the low-risk group included many factors involved in the innate immune response, proteolysis, protease inhibition, oxidation reduction, and others (Fig 2). Several of these proteins have known antimicrobial roles, such as S100 proteins, mucins, leukocyte elastase inhibitor, and thioredoxin. Furthermore protein S100A7, leukocyte elastase inhibitor, and thioredoxin were previously found to be overexpressed in HESN individuals in other proteomic studies [3,15].

Interestingly, three intracellular proteins were found to be commonly overabundant in the cationic protein-depleted secretions of all HIV neutralizing groups: SH3 domain-binding glutamic acid-rich-like protein 2 (SH3BGRL2), Synaptic vesicle membrane protein VAT-1 homolog (VAT-1) and Myristoylated alanine-rich C-kinase substrate protein (MARCKs). All three were found at higher levels in the sex worker groups CVS than the CVS of low-risk women. These proteins are associated with functions such as antioxidant defense, epidermal repair and actin remodeling, respectively. Furthermore, there were two secreted proteins commonly overabundant in the cationic protein-depleted secretions from both HESN groups: Poly(U)-specific endoribonuclease (ENDOU) and Leukocyte elastase inhibitor (SERPIN B1), and two secreted proteins commonly underabundant: Protein S100-A11 (S100A11) and Mucin-5AC (MUC5AC). These factors are of particular interest due to their secreted nature and their known antimicrobial and/or immune-related functions.

**Discussion**

This work demonstrates that genital secretions from HIV-seronegative and HIV-seropositive sex workers have an intrinsic capacity to neutralize HIV in vitro, which extends previous findings on low-risk uninfected women [7,25,37]. However in contrast, we here showed that when cationic proteins were experimentally depleted from the samples of the female sex workers, the HIV-neutralizing activity remained. Proteomic analysis revealed non-cationic proteins not previously associated with antiviral activity to be present in the HIV-neutralizing secretions.
This is the first time any HIV-neutralizing activity has been demonstrated in the cation-depleted protein fraction of cervicovaginal mucosa.

Three proteins were found overabundant and common to all sex worker groups, including SH3BGRL2, VAT-1 and MARCKS. None of these factors have been described to have direct antiviral activity in the current literature, but we here speculate about their potential indirect effects on various pathways involved in the mucosal defense against HIV infection. These proteins are predominantly found intracellularly or within extracellular exosomes. VAT-1 is an integral membrane protein that belongs to a superfamily of medium-chain dehydrogenases/reductases and strongly resembles quinone oxidoreductases and zeta-crystallins [38]. VAT-1 has been shown to be an important calcium-regulated activator of epithelial cells which is

| Protein Name                                   | Gene Name   | General Function                      | Log2 Fold change difference | P-value |
|------------------------------------------------|-------------|---------------------------------------|----------------------------|---------|
| Cytochrome c *                                 | CYSC        | Apoptosis/transport                    | 6.351                      | 0.043   |
| DNAJ homolog subfamily B member 1 *           | DNAJB1      | Stress response                        | 5.340                      | 0.001   |
| Poly(U)-specific endoribonuclease              | ENDOU       | Immune response/proteolysis           | 4.757                      | 0.049   |
| 60S ribosomal protein L4                       | RPL4        | Translation                            | 4.311                      | 0.033   |
| Eukaryotic translation initiation factor 2 subunit 2 | EIF2S2  | Protein biosynthesis                   | 4.085                      | 0.000   |
| Caspase-14                                     | CASP14      | Epidermal differentiation              | 3.445                      | 0.033   |
| Microtubule-associated protein 4               | MAP4        | Cell division                          | 2.731                      | 0.004   |
| Synaptic vesicle membrane protein VAT-1 homolog| VAT1        | Epidermal repair, oxidoreductase activity | 2.674                  | 0.027   |
| Tubulin polymerization-promoting protein family member 3 | TPPP3 | Microtubule bundle formation          | 2.606                      | 0.017   |
| Aldehyde dehydrogenase, dimeric NADP-prefering | ALDH3A1    | Catabolic process                      | 2.415                      | 0.026   |
| SH3 domain-binding glutamic acid-rich-like protein 2 | SH3BGR2 | Potential antioxidant defense          | 2.285                      | 0.046   |
| Nucleobindin-1                                 | NUCB1       | Calcium homeostasis                    | 2.283                      | 0.041   |
| Myristoylated alanine-rich C-kinase substrate  | MARCKS      | Actin Cross-linking                     | 2.191                      | 0.047   |
| Acyl-CoA-binding protein                       | DBI         | Transport                              | 2.146                      | 0.018   |
| Leukocyte elastase inhibitor                   | SERPINB1    | Protease Inhibition                    | 1.871                      | 0.015   |
| UV excision repair protein RAD23 homolog B     | RAD23B      | Ubiquitin conjugation pathway          | 1.584                      | 0.010   |
| Vinculin                                       | VCL         | Cell adhesion                          | 1.547                      | 0.001   |
| Lyosomal protective protein                    | CTSA        | Proteolysis                            | 1.453                      | 0.032   |
| Thioredoxin                                    | TXN         | Innate immune response, oxidoreductase activity | 1.330                  | 0.034   |
| Protein S100-A7                                | S100A7      | Innate immune response                 | 1.267                      | 0.025   |
| Barrier-to-autointegration factor *            | BANF1       | Host-virus Interaction                 | 1.143                      | 0.032   |
| Prothrombin                                    | F2          | Acute phase response                   | -4.092                     | 0.014   |
| Protein S100-A11                               | S100A11     | keratinocyte differentiation           | -1.915                     | 0.036   |
| Mucin-5AC (Fragments)                          | MUC5AC      | Mucosa component, anti-adhesion        | -1.734                     | 0.035   |
| Arachidonate 12-lipoxygenase, 12S-type         | ALOX12      | Lipid metabolism                      | -1.373                     | 0.043   |
| Keratin, type II cytoskeletal 6B               | KRT6B       | Structural                             | -1.065                     | 0.014   |

* General functions are based on each protein’s gene ontology obtained from the UniProt website.

* Statistical significance was deduced via Student’s T-test, p < 0.05.

* denotes a known association with HIV-1.

doi:10.1371/journal.pone.0130404.t001
### Table 2. Proteins found to be significantly overabundant (A) and underabundant (B) in the cationic protein-depleted cervicovaginal secretions of HIV-exposed seronegative sex workers (<3 years) compared to HIV seronegative low-risk controls.

| Protein Name                                      | Gene Name       | Log2 Fold Change Difference | P     |
|---------------------------------------------------|-----------------|----------------------------|-------|
| **(A) OVERABUNDANT PROTEINS**                     |                 |                            |       |
| Cytochrome c                                      | CYCS Apoptosis/transport | 6.344                     | 0.001 |
| DnaJ homolog subfamily B member 1                 | DNAJB1 Stress response | 5.200                     | 0.012 |
| Hepatoma-derived growth factor                     | HDGF Transcription regulation | 4.874                     | 0.041 |
| Glutathione S-transferase P                       | GSTP1 Anti-inflammation | 4.446                     | 0.008 |
| Poly(U)-specific endoribonuclease                 | ENDOU Immune response/proteolysis | 4.097                     | 0.044 |
| 60S ribosomal protein L4                          | RPL4 Translation | 4.002                     | 0.014 |
| Quinone oxidoreductase PIG3                       | TP53I3 Stress response | 3.665                     | 0.025 |
| BAG family molecular chaperone regulator 3       | BAG3 Anti-apoptosis | 3.584                     | 0.009 |
| Serum albumin                                     | ALB Acute phase response | 3.542                     | 0.012 |
| Synaptic vesicle membrane protein VAT-1 homolog  | VAT1 Epidermal repair, oxidoreductase activity | 3.334                     | 0.001 |
| SH3 domain-binding glutamic acid-rich-like protein 2 | SH3BGR2 Potential antioxidant defense [26] | 2.836                     | 0.013 |
| Heterogeneous nuclear ribonucleoprotein Q        | SYNCRIP Host-virus Interaction | 2.542                     | 0.006 |
| Myristoylated alanine-rich C-kinase substrate     | MARCKS Actin cross-linking | 2.317                     | 0.000 |
| Phosphoglucomutase-2                              | PGAM1 Glucose metabolism | 2.286                     | 0.027 |
| Metallothionein-2                                 | MT2A Ion homeostasis | 2.279                     | 0.013 |
| ADP-sugar pyrophosphatase                         | NUDT5 Nucleotide metabolic process | 2.205                     | 0.025 |
| Ubiquitin-40S ribosomal protein S27a              | RPS27A Innate immune response | 2.141                     | 0.004 |
| Nucleobindin-1                                    | NUCB1 Calcium homeostasis | 1.971                     | 0.024 |
| STE20-like serine/threonine-protein kinase        | SLK Apoptosis    | 1.909                     | 0.047 |
| Caspase-14                                        | CASP14 Epidermal differentiation | 1.908                     | 0.029 |
| Clathrin light chain B                            | CLTB Vesicle-mediated transport | 1.849                     | 0.018 |
| Proteasome activator complex subunit 1            | PSME1 Immunoproteasome assembly | 1.598                     | 0.023 |
| Lysosomal protective protein                      | CTSA Proteolysis | 1.564                     | 0.028 |
| Kallikrein-6                                      | KLK6 Proteolysis | 1.543                     | 0.018 |
| Barrier-to-autointegration factor *                | BANF1 Host-virus Interaction | 1.538                     | 0.015 |
| Tubulin polymerization-promoting protein family member 3 | TPPP3 Microtubule bundle formation | 1.348                     | 0.009 |
| Leukocyte elastase inhibitor                      | SERPINB1 Protease Inhibition | 1.293                     | 0.008 |
| Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial | ECH1 Lipid metabolism | 1.234                     | 0.004 |
| Cathepsin B                                       | CTSB Innate immune response/proteolysis | 1.198                     | 0.026 |
| Ly6/PLAUR domain-containing protein 3             | LYPD3 Cell-matrix adhesion | 1.191                     | 0.039 |

| **(B) UNDERABUNDANT PROTEINS**                     |                 |                            |       |
| Non-histone chromosomal protein HMG-17            | HMGN2 Chromatin organization | -6.516                    | 0.024 |
| Coactosin-like protein                            | COTL1 Defense response to fungus | -5.413                    | 0.017 |
| Keratin, type II cytoskeletal 2 oral              | KRT76 Structural | -4.856                     | 0.027 |
| Epidermal growth factor receptor kinase substrate 8-like protein 1 | EPS8L1 Cytoskeleton remodeling | -3.318                     | 0.038 |
| Zyxin *                                          | ZYX Cell adhesion | -2.753                     | 0.025 |
| BPI fold-containing family B member 1            | BPIFB1 Innate immune response | -2.388                    | 0.049 |
| Keratin, type II cytoskeletal 2 epidermal         | KRT2 Keratinization | -2.188                     | 0.041 |
| Granulins                                         | GRN Inflammation, embryo implantation | -2.087                    | 0.011 |
| IgGFc-binding protein                             | FCGBP Maintenance of mucosal structure | -2.052                    | 0.044 |
| Protein S100-A11                                  | S100A11 keratinocyte differentiation | -1.974                    | 0.003 |
| Mucin-5AC                                         | MUC5AC Mucosa component, anti-adhesion | -1.708                    | 0.015 |

(Continued)
required for epidermal repair [39]. Elevated levels of epidermal repair proteins may be important for maintaining an intact physical barrier within the genital tract which is critical for preventing pathogen entry. VAT-1 also has the capacity to function as an oxidoreductase which may further contribute to the overall antioxidant defense in the mucosa of the female genital tract. SH3BGRL2 is believed to be another oxidoreductase belonging to the Thioredoxin-like superfamily as it has a homologous thioredoxin-like fold [26]. Certain Thioredoxin-like family members such as peroxiredoxins have been shown to inhibit HIV replication in vitro [40]. Based on SH3BGRL2’s homology with proteins known to affect pathways important for HIV replication and known HIV inhibitors, it is an excellent biomarker for future studies. MARCKS, on the other hand, has functions in cross-linking actin, binding calcium-calmodulin, as well as integrins [41,42]. It has been speculated that these molecular functions contribute to biological processes such as phagocytosis, secretion and/or membrane recycling which are all important defense mechanisms against invading pathogens. As these proteins were all commonly overabundant in the secretions of sex workers compared to low-risk controls, they present as novel biomarkers for further investigations on their direct or indirect role in HIV infection.

Table 2. (Continued)

| Protein Name | Gene Name | General Function | Log₂ Fold Change Difference | P |
|--------------|-----------|------------------|-----------------------------|---|
| Phosphoglycerate mutase 1 | PGM2 | Glycolysis | -1.028 | 0.028 |

a General functions are based on each protein’s gene ontology obtained from the UniProt website.

b Statistical significance was deduced via Student’s T-test, p < 0.05.

Table 3. Proteins found to be significantly overabundant (A) and underabundant (B) in the cationic protein-depleted cervicovaginal secretions of HIV-positive sex workers compared to HIV seronegative low-risk controls.

| Protein Name                      | Gene Name | General Function | Log₂ Fold Change Difference | P-value |
|-----------------------------------|-----------|------------------|-----------------------------|---------|
| **(A) OVERABUNDANT PROTEINS**     |           |                  |                             |         |
| Keratin, type I cytoskeletal 24   | KRT24     | Structural       | 5.049                       | 0.015   |
| SH3 domain-binding glutamic acid-rich-like protein 2 | SH3BGRL2 | Potential antioxidant defense [26] | 2.826 | 0.018 |
| Synaptic vesicle membrane protein VAT-1 homolog | VAT1 | Epidermal repair, oxidoreductase activity | 2.739 | 0.036 |
| Myristoylated alanine-rich C-kinase substrate | MARCKS | Actin cross-linking | 2.590 | 0.007 |
| Phosphoglucomutase-2              | PGM2      | Glucose metabolism | 1.735 | 0.037 |
| 60S acidic ribosomal protein P0    | RPLP0     | Host-virus interaction | 1.717 | 0.039 |
| UV excision repair protein RAD23 homolog B | RAD23B | Ubiquitin conjugation pathway | 1.445 | 0.028 |
| Vinculin                          | VCL       | Cell adhesion    | 1.060                       | 0.013   |
| **(B) UNDERABUNDANT PROTEINS**    |           |                  |                             |         |
| Keratin, type II cytoskeletal 2 oral | KRT76    | Structural       | -5.327                      | 0.003   |
| Transcobalamin-1                  | TCN1      | Ion transport    | -2.994                      | 0.038   |
| Phosphoglycerate kinase 1         | PGK1      | Glycolysis       | -1.687                      | 0.046   |

a General functions are based on each protein’s gene ontology obtained from the UniProt website.

b Statistical significance was deduced via Student’s T-test, p < 0.05.

doi:10.1371/journal.pone.0130404.t002

doi:10.1371/journal.pone.0130404.t003
New Potential HIV-Neutralizing Factors

A. Underabundant HESN >3 years Overabundant
- Actin Remodeling
- Epidermal Repair
- Innate Immune Response
- Regulation of Apoptosis
- Regulation of Peptidase Activity
- HIV Infection
- Regulation of Cell Migration
- Oxidation Reduction
- Proteolysis
- Epidermal Development

Number of Differentially Expressed Proteins Associated with a Particular Biological Process

B. Underabundant HESN <3 years Overabundant
- Oxidation Reduction
- Actin Remodeling
- Epidermal Repair
- Adhesion
- Epidermal Development
- HIV Infection
- Regulation of Peptidase Activity
- Innate Immune Response
- Negative Regulation of Apoptosis
- Proteolysis
- Induction of Apoptosis
- Translational Elongation

Number of Differentially Expressed Proteins Associated with a Particular Biological Process

C. Underabundant HIV Positive Overabundant
- Oxidation Reduction
- Actin Remodeling
- Proteolysis
- Epidermal Repair
- Regulation of Peptidase Activity
- Glycolysis/Gluconeogenesis

Number of Differentially Expressed Proteins Associated with a Particular Biological Process
Certain proteins that were found to be overabundant in the CVS of the HESN>3yr group have previously been associated with protective immunity in comparable HIV-exposed seronegative cohorts including protein S100A7, leukocyte elastase inhibitor, and thioredoxin [3]. The family of S100 proteins, such as protein S100A7, includes calcium ion-binding proteins that are known to be associated with native antimicrobial activity [43], are derived from epithelial cells, and are secreted in response to external pathogens. Protein S100A7, also known as Psoriasin has been specifically implicated in the innate immunity of the epidermis by enhancing barrier function via the promotion of keratinocyte differentiation and the strengthening of tight junctions [44]. If and when protein S100A7 is induced under inflammatory conditions, it is also known to play a role in the chemotaxis of immune cells including neutrophils and T lymphocytes [45]. This protein’s association with increased barrier integrity could help prevent infection and the recruitment of immune cells may help in viral clearance. However, the fine interplay between the recruitment of HIV target cells for viral clearance versus infection propagation is still not fully understood.

Thioredoxin (TXN) is a disulfide oxidoreductase with innate immune function as mentioned above. TXN plays key roles in reducing reactive-oxygen species-mediated inflammation [46] and promoting cell growth and proliferation [47]. TXN also exhibits dose-dependent chemotactic effects such that at low concentrations it is chemotactic for various immune cells including neutrophils and at high concentrations it suppresses leukocyte chemotaxis and extravasation [46,48]. Furthermore, there is evidence that TXN has the capacity to neutralize HIV in macrophages in vitro, however it is noteworthy to mention that the same study found that TXN’s cleavage product, Eosinophil cytotoxicity-enhancing factor had enhancing effects on HIV infection and TXN is often quickly cleaved upon entering circulation [49]. It is therefore, hypothesized that it is more likely that secreted TXN exerts its protective effects by suppressing leukocyte extravasation [46].

Leukocyte elastase inhibitor (SERPINB1), a protein associated with the HESN phenotype in previous literature was also found commonly overabundant in both HESN groups in this study [3]. SERPINB1 belongs to the serine protease inhibitor family of antiproteases, and inhibits both elastase-like and chymotrypsin-like proteases, including Cathespin G. It has been implicated in providing defense against microorganisms at mucosal surfaces by protecting against protease-mediated inflammatory damage of the epithelium induced during bacterial infections, and promoting wound healing [50]. Other serine protease inhibitors such as Serpin A1, Secreted leukocyte protease inhibitor and Elafin have been associated with anti-HIV functionality in vitro [51–54]. Therefore, SERPINB1 may represent a novel target for further study of its potential to neutralize HIV, thus preventing infection.

Poly(U)-specific endoribonuclease (ENDOU) was found commonly overabundant amongst the CVS of HESN individuals within this study. ENDOU is a secreted endoribonuclease that cleaves single-stranded RNA [55]. Based on the current literature, it is mostly commonly expressed in placental tissue and in tumours. Not much is known about this protein making it a novel protein for future studies.

Interestingly, there were also two proteins found commonly under abundant in the CVS of HESN individuals compared to the CVS of low-risk women, protein S100A11 and Mucin 5-AC. S100A11 is also a member of the S100 family, a calcium ion-binding protein expressed...
by epithelial cells. S100A11 has a dual functionality in keratinocyte growth regulation such that when it is found intracellularly, it suppresses growth and facilitates differentiation and cornification of keratinocytes [56], whereas when it is found extracellularly, it in fact promotes keratinocyte growth [57]. Mucin-5AC (MUC5AC) is a glycoprotein secreted on mucosal surfaces generating another physical protective barrier against microorganisms. MUC5AC has been shown to be induced from epithelial cells by neutrophil elastase in the airways, and may be induced in a similar fashion at other mucosal sites such as the female genital tract [58].

The up-regulation and down-regulation of specific factors at the mucosa of the female genital tract of HIV-exposed sex workers such as those identified in this study may be a result of frequent sexual encounters, their higher risk of genital exposure to seminal fluid from different individuals, and/or from previous STIs. These are all known risk factors for inflammation, disrupted genital microflora and altered composition of the innate immune proteome [59]. It is possible that the up-regulation of some of these factors may be the result of increased Toll-like receptor (TLR) expression in the cervical epithelial cells of HIV-resistant women [60]. Further fractionation is needed to define which of these factors constitute the majority of the non-cationic protein neutralizing activity. Furthermore, only Clade A isolates were tested in this study, therefore we can only attest to the enhanced neutralizing activity of the cationic protein-depleted secretions of female sex workers against these isolates. It is also possible that HIV neutralizing IgA antibodies [19,61] as well as other peptides, below the detection limit of the mass spectrometry analysis, were present and associated with HIV-neutralizing activity. In any case the factors identified in this study and their HIV inhibitory capacity warrant further investigation in vitro.

Understanding factors that modulate HIV infection at the female genital tract mucosa is important for the development and implementation of novel antiviral compounds including microbicides. This study increases our knowledge of the neutralizing capacity of genital secretions and identifies new potential antimicrobial factors important for female genital tract immunity.

Supporting Information
S1 Table. Complete details on the proteomic data set.
(XLSX)

Acknowledgments
The authors would like to thank all the study participants for donating their samples, without which this study would not be possible.

Author Contributions
Conceived and designed the experiments: TH KB. Performed the experiments: TH ALC KDMB. Analyzed the data: TH ALC KDMB. Contributed reagents/materials/analysis tools: AMC AB KB TBB FP LM GRW JK. Wrote the paper: KDMB AB KB.

References
1. Broliden K (2010) Innate molecular and anatomic mucosal barriers against HIV infection in the genital tract of HIV-exposed seronegative individuals. J Infect Dis 202 Suppl 3: S351–355. doi: 10.1086/655964 PMID: 20887223
2. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. (2000) Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14: 1917–1920. PMID: 19997395
3. Burgener A, Boutlier J, Wachihi C, Kimani J, Carpenter M, Westmacott G, et al. (2008) Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. J Proteome Res 7: 4446–4454. doi: 10.1021/pr800406r PMID: 18707157

4. Jendrysik MA, Ghassemi M, Graham PJ, Boksa LA, Williamson PR, Novak RM (2005) Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Infect Dis 192: 630–639. PMID: 16028132

5. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, et al. (2009) Elevated elafrin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 23: 1669–1677. doi: 10.1097/QAD.0b013e32832ea643 PMID: 19553806

6. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershov RC, et al. (2007) Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 14: 1102–1107. PMID: 17671228

7. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM (2005) Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 175: 7560–7567. PMID: 16301665

8. Chappell CA, Rohan LC, Moncla BJ, Wang L, Meyn LA, Bunke G, et al. (2014) The effects of reproductive hormones on the physical properties of cervicovaginal fluid. Am J Obstet Gynecol 211: 226 e221–227. doi: 10.1016/j.ajog.2014.03.041 PMID: 24662718

9. Morrison C, Fichorova RN, Mauck C, Chen PL, Kwok C, Chippato T, et al. (2014) Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr 66: 109–117. doi: 10.1097/QAI.0000000000000103 PMID: 24413042

10. Patel MV, Fahey JV, Rossol RM, Wira CR (2013) Innate immunity in the vagina (part I): estradiol inhibits its HBD2 and elafrin secretion by human vaginal epithelial cells. Am J Reprod Immunol 69: 463–474. doi: 10.1111/aji.12078 PMID: 23398087

11. Rahman S, Rabbani R, Wachihi C, Kimani J, Plummer FA, Ball TB, et al. (2013) Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders. Am J Reprod Immunol 69: 64–72. doi: 10.1111/aji.12014 PMID: 22971020

12. Doerflinger SY, Throop AL, Herbst-Kralovetz MM (2014) Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J Infect Dis 209: 1989–1999. doi: 10.1097/INF.0000000000000284 PMID: 24405360

13. Burgener A, Tjemlund A, Kaldensjo T, Abou M, McCorrister S, Westmacott GR, et al. (2013) A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression. J Virol 87: 5141–5150. doi: 10.1128/JVI.03347-12 PMID: 23449785

14. Shaw JL, Smith CR, Diamandis EP (2007) Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 6: 2859–2865. PMID: 17567164

15. Burgener A, Rahman S, Ahmad R, Lajoie J, Ramdhahin S, Mesa C, et al. (2011) Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J Proteome Res 10: 5139–5149. doi: 10.1021/pr200596r PMID: 21973077

16. Gwyer Findlay E, Currie SM, Davidson DJ (2013) Cationic host defence peptides: potential as antimicrobial therapeutics. BioDrugs 27: 479–493. doi: 10.1007/s40259-013-0039-0 PMID: 23649937

17. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, et al. (1996) Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348: 1347–1351. PMID:8918278

18. Embree JE, NJenga S, Datta P, Nagelkerke NJ, Ndinya-Achola JO, Mohammed Z, et al. (2000) Risk factors for postnatal mother-child transmission of HIV-1. AIDS 14: 2535–2541. PMID: 11101065

19. Hirbod T, Gaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, et al. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22: 727–735. doi: 10.1097/QAD.0b013e328256664 PMID: 18356602

20. Hirbod T, Kong X, Kigozi G, Ndyanabo A, Serwadda D, Prodger JL, et al. (2014) HIV Acquisition Is Associated with Increased Antimicrobial Peptides and Reduced HIV Neutralizing IgA in the Foreskin Prepuce of Uncircumcised Men. PLoS Pathog 10: e1004416. doi: 10.1371/journal.ppat.1004416 PMID: 25275513

21. Lizeng Q, Skott P, Sourial S, Nilsson C, Andersson SS, Ehlund M, et al. (2003) Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 308: 225–232. PMID: 12706073

22. Valore EV, Park CH, Igrei SL, Ganz T (2002) Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 187: 561–568. PMID: 12237628
23. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57. doi: 10.1038/nprot.2008.211 PMID: 19131956

24. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1–13. doi: 10.1093/nar/gkn923 PMID: 19033363

25. Levinson P, Choi RY, Cole AL, Hibdin T, Rhedin S, Payne B, et al. (2012) HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. PLoS One 7: e31996. doi: 10.1371/journal.pone.0031996 PMID: 22389677

26. Mazzocco M, Maffei M, Egeo A, Vergano A, Arrigo P, Di Lisi R, et al. (2002) The identification of a novel highly conserved small proteins related to Thioredoxin Superfamily. Gene 291: 233–239. PMID: 12095696

27. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, et al. (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4: 495–504. doi: 10.1016/j.chom.2008.10.004 PMID: 18976975

28. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921–926. doi: 10.1126/science.1152725 PMID: 18187620

29. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, et al. (2008) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135: 49–60. doi: 10.1016/j.cell.2008.07.032 PMID: 18854154

30. Martinez O, Johnson J, Manicassamy B, Rong L, Olinger GG, Hensley LE, et al. (2010) Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol 12: 148–157. doi: 10.1111/j.1462-5822.2009.01385.x PMID: 19775255

31. Ang F, Wong AP, Ng MM, Chu JJ (2010) Small interference RNA profiling reveals the essential role of human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of calcium-regulated activation marker of human epithelial cells. Arch Dermatol Res 295: 203–210. PMID: 12898150

32. Geiben-Lynn R, Kursar M, Brown NV, Addo MM, Shau H, Lieberman J, et al. (2003) HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J Biol Chem 278: 1569–1574. PMID: 12421807

33. Koch J, Fokkens J, Timmermans M, Fink W, Witzbach A, Kramer MD, et al. (2003) Human VAT-1: a calcium-regulated activation marker of human epithelial cells. Arch Dermatol Res 295: 203–210. PMID: 12898150

34. Ghosh M, Fahey JV, Shen Z, Cu-Uvin S, Wu Z, et al. (2010) Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5: e11366. doi:10.1371/journal.pone.0011366 PMID: 20614007

35. Persson B, Zigler JS Jr., Jornvall H (1994) A super-family of medium-chain dehydrogenases/reductases (MDR). Sub-lines including zeta-crystallin, alcohol and polyol dehydrogenases, quinone oxidoreductase enoyl reductases, VAT-1 and other proteins. Eur J Biochem 229: 15–22. PMID: 8221380

36. Remoli AL, Marsili G, Perrotti E, Gallerani E, Ileri R, Nappi F, et al. (2006) Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 396: 371–380. PMID: 16512786

37. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, et al. (2010) Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463: 818–822. doi:10.1038/ nature08760 PMID: 20081832

38. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921–926. doi: 10.1126/science.1152725 PMID: 18187620

39. Ray G, Kumar V, Kapoor AK, Dutta AK, Batra S (1999) Status of antioxidants and other biochemical abnormalities in children with dengue fever. J Trop Pediatr 45: 4–7. PMID: 10191585

40. Ghosh M, Fahey JV, Shen Z, Cu-Uvin S, Wu Z, et al. (2010) Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 5: e11366. doi:10.1371/journal.pone.0011366 PMID: 20614007

41. Remoli AL, Marsili G, Perrotti E, Gallerani E, Ileri R, Nappi F, et al. (2006) Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 396: 371–380. PMID: 16512786

42. Marche I, Marchand F, Gobert A, Prat A, Bernier E, Irelan JT, et al. (2009) Identification of host factors required for HIV replication. Cell Host Microbe 4: 495–504. doi: 10.1016/j.chom.2008.10.004 PMID: 18976975
43. Morizane S, Gallo RL (2012) Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 39: 225–230. doi: 10.1111/j.1346-8138.2011.01483.x PMID: 22352846

44. Hattori F, Kiatsu-rayancon C, Okumura K, Ogawa H, Ikeda S, Okamoto K, et al. (2014) The antimicrobial protein S100A7/psoriasin enhances the expression of keratinocyte differentiation markers and strengthens the skin’s tight junction barrier. Br J Dermatol 171: 742–753. doi: 10.1111/bjd.13125 PMID: 24842328

45. Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B, et al. (1996) Psoriasin: a novel chemotactic protein. J Invest Dermatol 107: 5–10. PMID: 8752830

46. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, et al. (2001) Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A 98: 15143–15148. PMID: 11742067

47. Nakamura H, Nakamura K, Yodoi J (1997) Redox regulation of cellular activation. Annu Rev Immunol 15: 351–369. PMID: 9143692

48. Schenk H, Vogt M, Droge W, Schulze-Osthoff K (1996) Thioredoxin as a potent costimulus of cytokine expression. J Immunol 156: 765–771. PMID: 8543831

49. Newman GW, Balcewicz-Sablinska MK, Guarneria JR, Remold HG, Silberstein DS (1994) Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1. J Exp Med 180: 359–363. PMID: 8006594

50. Benarafa C, Priebe GP, Remold-O'Donnell E (2007) The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med 204: 1901–1909. PMID: 17664292

51. Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, et al. (2007) Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129: 263–275. PMID: 17448989

52. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, et al. (1997) Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 3 Suppl 1: S64–69. PMID: 9456660

53. Hocini H, Becquart P, Bouhial H, Adle-Biassette H, Kazatchkine MD, Belec L (2000) Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol 7: 515–518. PMID: 10799472

54. Jasinghe VJ, Peyrotte EA, Meyers AF, Gajanayaka N, Ball TB, Sandstrom P, et al. (2013) Human eLafin Inhibits HIV-1 Replication in Its Natural Target Cells. Biore Open Access 2: 128–137. doi: 10.1089/biores.2012.0275 PMID: 23593565

55. Laneve P, Gioia U, Ragno R, Altrieri F, Di Franco C, Santini T, et al. (2008) The tumor marker human placental protein 11 is an endoribonuclease. J Biol Chem 283: 34712–34719. doi: 10.1074/jbc.M805759200 PMID: 18935097

56. Kouno T, Mizuguchi M, Sakaguchi M, Makino E, Mori Y, Shinoda H, et al. (2008) The structure of S100A11 fragment explains a local structural change induced by phosphorylation. J Pept Sci 14: 1129–1138. doi: 10.1002/pjc.1050 PMID: 18618420

57. Sakaguchi M, Huh NH (2011) S100A11, a dual growth regulator of epidermal keratinocytes. Amino Acids 41: 797–807. doi: 10.1007/s00726-010-0747-4 PMID: 20872027

58. Zhou J, Perelman JM, Kolosov VP, Zhou X (2013) Neutrophil elastase induces MUC5AC secretion via protease-activated receptor 2. Mol Cell Biochem 377: 75–85. doi: 10.1007/s11010-013-1572-3 PMID: 23392769

59. Wira CR, Fahey JV, Rodriguez-Garcia M, Shen Z, Patel MV (2014) Regulation of Mucosal Immunity in the Female Reproductive Tract: The Role of Sex Hormones in Immune Protection Against Sexually Transmitted Pathogens. Am J Reprod Immunol.

60. Yao XD, Omange RW, Henrick BM, Lester RT, Kimani J, Ball TB, et al. (2013) Acting locally: innate mucosal immunity in resistance to HIV-1 infection in Kenyan commercial sex workers. Mucosal Immunol.

61. Choi RY, Levinson P, Guthrie BL, Lohman-Payne B, Bosire R, Liu AY, et al. (2012) Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples. AIDS 26: 2155–2163. doi: 10.1097/QAD.0b013e328359b99b PMID: 22948273